1st Quarter - Report

ANGELA STEWART for EISAI, INC

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S1376) Department of Defense Appropriations Bill for 2016 (HR2685)

LobbyistCovered position, as disclosed
ANGELA STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1735 (114th), H.R. 2685 (114th)

Medicare/Medicaid MMM

Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Medicare Access and CHIP Reauthorization Act of 2015 (HR2) SGR Repeal and Medicare Provider Payment Modernization Act of 2015 (S810/HR1470) Treat and Reduce Obesity Act of 2015 (HR2404)

LobbyistCovered position, as disclosed
ANGELA STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1470 (114th), H.R. 2 (114th), H.R. 2404 (114th)

Pharmacy PHA

DEA scheduling of controlled substances Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639/S. 481)

LobbyistCovered position, as disclosed
ANGELA STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 481 (114th), H.R. 639 (114th)

Budget/Appropriations BUD

Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.

LobbyistCovered position, as disclosed
ANGELA STEWART —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.Con.Res. 27 (114th), S.Con.Res. 11 (114th)

Health Issues HCR

Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54)Regulatory and legislative health care issues, including the 340B program

LobbyistCovered position, as disclosed
ANGELA STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.